Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
6 May 2014 | By Novartis
Novartis presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR in patients with acromegaly for whom current standard of care provides inadequate disease control...